Oxana Denisova
PhD
oxana.denisova@utu.fi Tykistökatu 6 Turku Työhuone: 4123 ORCID-tunniste: https://orcid.org/0000-0002-7041-3842 |
Cancer cell signaling; kinases; protein phosphatases; anticancer and antiviral agents, virus-host interaction
INFLAMES Flagship
Education and degrees completed
2014 PhD in Medicine, Faculty of Medicine, University of Helsinki, Finland.
2007 MSc in Biology (Molecular Biology) (Hons.), Lobachevsky State University of Nizhny Novgorod, Russia.
Current position
09/2022 – to date Senior Postdoc, Turku Bioscience Centre, University of Turku & Åbo Akademi University, Turku, Finland
Previous work experience
01/2015 – 07/2022 Postdoctoral Researcher, Novel targeted therapy for human malignant glioblastoma with Professor Jukka Westermarck, Turku Bioscience Centre, University of Turku & Åbo Akademi University, Turku, Finland
06/2011 – 05/2014 PhD Researcher, Influenza virus-host interactions and their modulation by small molecules with Docent Denis Kainov, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
10/2008 – 06/2011 Junior Researcher, Institute of Theoretical and Experimental Biophysics, Pushchino, Russia
09/2007 – 10/2008 Junior Researcher, Institute of Protein Research, Pushchino, Russia
09/2005 – 05/2007 Visiting Master student, Development of genomic approach for high-throughput analysis of CCWGG methylation with Professor Nicholas I. Matvienko, Molecular Biology Education Centre, Institute of Protein Research, Pushchino, Russia
Career breaks
05/2020 – 08/2021 Maternity leave
05/2016 – 08/2017 Maternity leave
I am a PhD-trained scientist with over 15 years of research experience in molecular biology, cell signaling, and anticancer therapy development. My current research focuses on brain cancer vulnerabilities, with a particular focus on glioblastoma and pediatric medulloblastoma. I have extensive expertise in preclinical in vivo models.
- PP2A inhibitor proteins CIP2A and PME-1 as medulloblastoma oncoproteins and therapy targets (2025)
- Molecular Oncology
(Abstrakti) - Targeting DUSP6 to combat therapy resistance and brain metastasis in HER2-positive breast cancer (2025)
- Molecular Oncology
(Abstrakti) - PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells (2023)
- Molecular Oncology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Protein phosphatase PP2A-based triple-strike therapy for medulloblastoma (2023)
- Molecular Oncology
(O2 Muu julkaisu ) - Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells (2022)
- Scientific Reports
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma (2020)
- Brain Communications
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide (2019)
- International Journal of Cancer
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells (2016)
- Cancer Research
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )